FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991762457> ?p ?o ?g. }

• W2991762457 endingPage "3500" @default.
• W2991762457 startingPage "3489" @default.
• W2991762457 abstract "The adjuvanted recombinant zoster vaccine (RZV) received its first marketing authorization in October 2017, for prevention of herpes zoster in individuals aged ≥50 years.We summarized safety information, following RZV administration, received by GSK via spontaneous adverse event (AE) reports submitted by healthcare providers, vaccine recipients and other reporters. Observed-to-expected (O/E) analyses were performed for selected outcomes: reports of death, Guillain-Barré syndrome and Bell's palsy. Standard case definitions were used to assess individual case reports. Data mining, using proportional reporting ratio and time-to-onset signal detection methods, was employed to identify RZV-AE pairs with disproportionate reporting or unexpected time-to-onset distribution.Between October 13, 2017 and February 10, 2019, an estimated 9.3 million doses were distributed and GSK received 15,638 spontaneous AE reports involving RZV. Most reports were classified as non-serious (95.3%) and originated from the United States (81.7%), where the majority of doses were distributed. Among reports with age or sex reported, individuals were mainly 50-69-year-olds (62.1%) and female (66.7%). Of all reports, 3,579 (22.9%) described vaccination errors, of which 82.7% were without associated symptoms. Of all vaccination error reports, most described errors of vaccine preparation and reconstitution (29.7%), inappropriate schedule or incomplete course of administration (26.7%), incorrect route of administration (16.4%), and storage errors (12.9%). The most commonly reported symptoms were consistent with the known RZV reactogenicity profile observed in clinical trials, including injection site reactions, pyrexia, chills, fatigue, headache. O/E analyses for selected outcomes and data mining analyses for all reported AEs did not identify any unexpected patterns.Review of the initial data from the post-marketing safety surveillance showed that the safety profile of RZV is consistent with that previously observed in pre-licensure clinical trials. Other studies are ongoing and planned, to continue generating real-world safety data and further characterize RZV." @default.
• W2991762457 created "2019-12-13" @default.
• W2991762457 creator A5030960735 @default.
• W2991762457 creator A5039860812 @default.
• W2991762457 creator A5043019770 @default.
• W2991762457 creator A5049588310 @default.
• W2991762457 creator A5072917391 @default.
• W2991762457 creator A5084091819 @default.
• W2991762457 creator A5084655314 @default.
• W2991762457 creator A5086902265 @default.
• W2991762457 date "2020-04-01" @default.
• W2991762457 modified "2023-10-04" @default.
• W2991762457 title "Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine" @default.
• W2991762457 cites W1578801232 @default.
• W2991762457 cites W175849078 @default.
• W2991762457 cites W1825495625 @default.
• W2991762457 cites W1921096549 @default.
• W2991762457 cites W1942950379 @default.
• W2991762457 cites W1974857187 @default.
• W2991762457 cites W1976590409 @default.
• W2991762457 cites W1996985859 @default.
• W2991762457 cites W1997799955 @default.
• W2991762457 cites W2001335332 @default.
• W2991762457 cites W2010207831 @default.
• W2991762457 cites W2013392553 @default.
• W2991762457 cites W2019536520 @default.
• W2991762457 cites W2028724075 @default.
• W2991762457 cites W2038787589 @default.
• W2991762457 cites W2040947756 @default.
• W2991762457 cites W2046085703 @default.
• W2991762457 cites W2072241077 @default.
• W2991762457 cites W2081522361 @default.
• W2991762457 cites W2086658590 @default.
• W2991762457 cites W2117671584 @default.
• W2991762457 cites W2137702559 @default.
• W2991762457 cites W2145347536 @default.
• W2991762457 cites W2152734304 @default.
• W2991762457 cites W2152757072 @default.
• W2991762457 cites W2177389296 @default.
• W2991762457 cites W2177952713 @default.
• W2991762457 cites W2209977920 @default.
• W2991762457 cites W2274646156 @default.
• W2991762457 cites W2334710445 @default.
• W2991762457 cites W2407540121 @default.
• W2991762457 cites W2519957152 @default.
• W2991762457 cites W2540671290 @default.
• W2991762457 cites W2546490381 @default.
• W2991762457 cites W2562485989 @default.
• W2991762457 cites W2563225576 @default.
• W2991762457 cites W2597387635 @default.
• W2991762457 cites W2784682748 @default.
• W2991762457 cites W2803748751 @default.
• W2991762457 cites W2915008616 @default.
• W2991762457 cites W2931264657 @default.
• W2991762457 cites W2975002447 @default.
• W2991762457 cites W580015659 @default.
• W2991762457 doi "https://doi.org/10.1016/j.vaccine.2019.11.058" @default.
• W2991762457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31818534" @default.
• W2991762457 hasPublicationYear "2020" @default.
• W2991762457 type Work @default.
• W2991762457 sameAs 2991762457 @default.
• W2991762457 citedByCount "13" @default.
• W2991762457 countsByYear W29917624572020 @default.
• W2991762457 countsByYear W29917624572021 @default.
• W2991762457 countsByYear W29917624572022 @default.
• W2991762457 countsByYear W29917624572023 @default.
• W2991762457 crossrefType "journal-article" @default.
• W2991762457 hasAuthorship W2991762457A5030960735 @default.
• W2991762457 hasAuthorship W2991762457A5039860812 @default.
• W2991762457 hasAuthorship W2991762457A5043019770 @default.
• W2991762457 hasAuthorship W2991762457A5049588310 @default.
• W2991762457 hasAuthorship W2991762457A5072917391 @default.
• W2991762457 hasAuthorship W2991762457A5084091819 @default.
• W2991762457 hasAuthorship W2991762457A5084655314 @default.
• W2991762457 hasAuthorship W2991762457A5086902265 @default.
• W2991762457 hasBestOaLocation W29917624571 @default.
• W2991762457 hasConcept C126322002 @default.
• W2991762457 hasConcept C147483822 @default.
• W2991762457 hasConcept C187212893 @default.
• W2991762457 hasConcept C195910791 @default.
• W2991762457 hasConcept C197934379 @default.
• W2991762457 hasConcept C203014093 @default.
• W2991762457 hasConcept C22070199 @default.
• W2991762457 hasConcept C2777105317 @default.
• W2991762457 hasConcept C2777589142 @default.
• W2991762457 hasConcept C2777704310 @default.
• W2991762457 hasConcept C2778594517 @default.
• W2991762457 hasConcept C2780791431 @default.
• W2991762457 hasConcept C2780801004 @default.
• W2991762457 hasConcept C60644358 @default.
• W2991762457 hasConcept C71924100 @default.
• W2991762457 hasConcept C86803240 @default.
• W2991762457 hasConceptScore W2991762457C126322002 @default.
• W2991762457 hasConceptScore W2991762457C147483822 @default.
• W2991762457 hasConceptScore W2991762457C187212893 @default.
• W2991762457 hasConceptScore W2991762457C195910791 @default.
• W2991762457 hasConceptScore W2991762457C197934379 @default.
• W2991762457 hasConceptScore W2991762457C203014093 @default.

• next